VYNE THERAPEUTICS INC

VYNE Therapeutics completed enrolment for a Phase IIb trial of VYN201 gel (repibresib) for non-segmental vitiligo. The study evaluates safety, efficacy, and pharmacokinetics of three doses versus a vehicle, with primary efficacy measured by F-VASI50 improvement at week 24. Top-line data expected mid-year.

VYNE Therapeutics announced progress in its VYN201 and VYN202 trials, with VYN201's Phase 2b vitiligo trial exceeding enrollment targets and expected to complete by December 2024, with results in mid-2025. VYN202's Phase 1a trial showed positive safety and pharmacokinetic data, with MAD results expected in Q4 2024. The company has a cash position of $70.2 million, sufficient through 2025.

VYNE Therapeutics completed enrollment in a phase 2b trial for repibresib gel, targeting nonsegmental vitiligo, with top-line results expected mid-2025. This trial evaluates the gel's efficacy, safety, and pharmacokinetics in 180 participants, aiming to address the significant unmet need for effective vitiligo treatments.

VYNE Therapeutics has completed enrolment for a Phase IIb trial of VYN201 gel (repibresib) for non-segmental vitiligo treatment. The study evaluates safety, efficacy, and pharmacokinetics of three doses compared to a vehicle, with primary efficacy measured by F-VASI50 improvement at week 24. Top-line data expected mid-year.

VYNE Therapeutics completed enrollment in its Phase 2b trial for VYN201 gel (repibresib) targeting nonsegmental vitiligo, with top-line data expected mid-2025. The USAN Council approved 'repibresib' as the non-proprietary name for VYN201, marking a significant development milestone.

VYNE Therapeutics completed enrollment for Phase 2b trial of VYN201 gel for nonsegmental vitiligo, with top-line data expected mid-2025. The USAN Council named the new chemical entity in VYN201 as 'repibresib'.

VYNE Therapeutics Inc. completed enrollment for a Phase 2b trial of VYN201 gel, a potential treatment for nonsegmental vitiligo, with top-line data expected mid-2025. The USAN Council named the active ingredient 'repibresib'. The trial evaluates its efficacy, safety, and pharmacokinetics in three doses over 24 weeks, with an optional 28-week extension.

VYNE Therapeutics completed enrollment for a Phase 2b trial of VYN201 gel, a potential treatment for nonsegmental vitiligo, with top-line data expected mid-2025. The USAN Council named the active ingredient 'repibresib'. The trial evaluates its efficacy and safety across three doses, aiming for significant improvement in vitiligo symptoms.

VYNE Therapeutics completed enrollment for a Phase 2b trial of VYN201 gel for nonsegmental vitiligo treatment, with top-line data expected mid-2025. The USAN Council named the active ingredient 'repibresib'. The trial evaluates efficacy, safety, and pharmacokinetics of repibresib gel in three doses over 24 weeks, with an optional 28-week extension.